🔍
Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+antibodies
30
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists
Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...
Published: 6/26/2025
|
Inventor(s):
Drew Pardoll
,
Joseph Barbi
,
Fan Pan
,
Hong Yu
,
Ching-Tai Huang
,
Xiaoyu Pan
,
Charles Drake
,
Jonathan Powell
Keywords(s):
Antibodies
,
Biologics
,
Cancers
,
Disease Indication
,
Immunotherapy
,
Infectious Diseases
,
Single
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Infectious Diseases
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
Therapeutic KCNK9 Antibody
Value PropositionFirst-in-Class Targeting of a Novel Oncogenic Ion Channel: Inhibiting KCNK9 represents a new therapeutic modality in cancers where traditional approachesTumor-Specific Overexpression Enables Selectivity: KCNK9 is overexpressed in various tumors (e.g., breast, gastric, lung) but has limited expression in most normal tissuesPro-Apoptotic...
Published: 6/27/2025
|
Inventor(s):
John Laterra
,
Amy Fulton
Keywords(s):
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology > Breast Cancer
,
Clinical and Disease Specializations > Oncology > Lung Cancer
,
Clinical and Disease Specializations > Oncology > Gastric Cancer
,
Technology Classifications > Therapeutic Modalities > Antibodies
Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...
Published: 6/26/2025
|
Inventor(s):
John Laterra
,
Han Sun
,
Min Li
,
Amy Fulton
Keywords(s):
Antibodies
,
Biologics
,
Breast Cancer
,
Cancers
,
Disease Indication
,
Lung Cancer
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Respiratory Diseases
,
Clinical and Disease Specializations > Women's Health
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Oncology > Breast Cancer
,
Clinical and Disease Specializations > Oncology > Lung Cancer
A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease
Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...
Published: 6/26/2025
|
Inventor(s):
Roger Johns
Keywords(s):
Antibodies
,
Biologics
,
Cardiovascular Diseases
,
Disease Indication
,
Hypertension
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Clinical and Disease Specializations > Cardiovascular
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Cardiovascular > Hypertension
Compositions and Methods for Treating Diseases and Conditions Associated with Activation of the NLRP3 Inflammasome
Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...
Published: 6/27/2025
|
Inventor(s):
Roger Johns
Keywords(s):
Category(s):
Clinical and Disease Specializations > Cardiovascular > Hypertension
,
Clinical and Disease Specializations > Cardiovascular > Heart Failure
,
Clinical and Disease Specializations > Infectious Diseases > Covid-19
,
Clinical and Disease Specializations > Inflammation
,
Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases
,
Clinical and Disease Specializations > Respiratory Diseases
,
Clinical and Disease Specializations > Respiratory Diseases > Chronic Obstructive Pulmonary Disorder
,
Clinical and Disease Specializations > Respiratory Diseases > Pulmonary Hypertension
,
Technology Classifications > Diagnostics
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Research Tools > Assays
,
Technology Classifications > Therapeutic Modalities > Antibodies
Sustained release formulations for fat reduction
JHU Ref #: C18159Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems....
Published: 6/27/2025
|
Inventor(s):
Laura Ensign
,
Yub Raj Neupane
,
Fatemeh Rajaii
Keywords(s):
Category(s):
Clinical and Disease Specializations > Endocrinology > Thyroid Disorders
,
Clinical and Disease Specializations > Metabolic Diseases > Obesity
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Small Molecules
Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1
Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...
Published: 6/27/2025
|
Inventor(s):
Jamie Spangler
,
Seth Ludwig
,
Angela Zhu
,
Rakeeb Kureshi
,
Helen Dooley
Keywords(s):
Category(s):
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Therapeutic Modalities > Antibodies
Antibodies associated with HIV control
Value Proposition· Target associated with viral load reduction identified from a large pool of study participants who had low level viremia· Potential to reduce disease severity in at-risk populations· Proactive approach to lower viral load in individuals who could become infected Unmet NeedHuman immunodeficiency virus (HIV) impacts millions...
Published: 6/27/2025
|
Inventor(s):
Susan Eshleman
,
Harry Larman
,
Kai Kammers
,
Oliver Laeyendecker
,
Wendy Grant-McAuley
Keywords(s):
Category(s):
Clinical and Disease Specializations > Infectious Diseases > HIV
,
Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies
Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis
Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid arthritis patients.Broadly applicable to other diseases...
Published: 6/27/2025
|
Inventor(s):
Erika Darrah
,
Felipe Andrade
,
Kristen Demoruelle
,
Elizabeth Redente
Keywords(s):
Category(s):
Clinical and Disease Specializations > Fibrosis
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications
,
Technology Classifications > Therapeutic Modalities
Polymers for Binding-Triggered Antibody Precipitation and Purification
Value PropositionResults in >97% precipitation yield, >88% elution yield of mAbsSimplified molecular design compared to elastin-like polypeptide (ELP)-based materialsDoes not need additional salt to achieve mAb precipitation and recoveryTechnology DescriptionResearchers at Johns Hopkins have developed a peptide-based platform technology using...
Published: 6/27/2025
|
Inventor(s):
Honggang Cui
,
Yi Li
,
David Stern
,
XuanKuo Xu
,
Lye Lin Lock
,
Jason Mills
,
Sanchayita Ghose
,
Zheng Jian Li
Keywords(s):
Category(s):
Clinical and Disease Specializations > Immunology
,
Clinical and Disease Specializations > Research Tools
,
Technology Classifications > Research Tools > Antibodies
,
Technology Classifications > Research Tools > Research Antibodies
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies
1
2
3
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum